168 related articles for article (PubMed ID: 36655833)
1. [Anti-angiogenic drugs and hypertension: from multidisciplinary collaboration to greater care].
Tunesi F; Simonini M; Sabetta G; Bergamini A; Cioffi R; Raiabiotti E; Manunta P; Vezzoli G; Mangili G; Lanzani CL
G Ital Nefrol; 2022 Dec; 39(6):. PubMed ID: 36655833
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
3. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
4. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.
Yagi K; Mitstui M; Zamami Y; Niimura T; Izawa-Ishizawa Y; Goda M; Chuma M; Fukunaga K; Shibata T; Ishida S; Sakurada T; Okada N; Hamano H; Horinouchi Y; Ikeda Y; Yanagawa H; Ishizawa K
Cancer Med; 2021 Jan; 10(1):164-172. PubMed ID: 33231381
[TBL] [Abstract][Full Text] [Related]
5. Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.
Bumes E; Rzonsa S; Hutterer M; Proescholdt M; Bogdahn U; Riemenschneider MJ; Uhl M; Wendl C; Hau P
J Neurooncol; 2016 Mar; 127(1):191-200. PubMed ID: 26721240
[TBL] [Abstract][Full Text] [Related]
6. [Vascular and renal effects of anti-angiogenic therapy].
Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
8. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
Plummer C; Michael A; Shaikh G; Stewart M; Buckley L; Miles T; Ograbek A; McCormack T
Br J Cancer; 2019 Jul; 121(2):109-116. PubMed ID: 31182765
[TBL] [Abstract][Full Text] [Related]
9. [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
Launay-Vacher V; Janus N; Beuzeboc P; Daniel C; Ray-Coquard I; Selle F; Rey JB; Jouannaud C; Spano JP; Thery JC; Morere JF; Goldwasser F; Mir O; Oudard S; Scotté F; Dorent R; Ludwig L; Deray G; Gligorov J
Bull Cancer; 2015 Nov; 102(11):906-14. PubMed ID: 26603517
[TBL] [Abstract][Full Text] [Related]
10. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
Horsley L; Marti K; Jayson GC
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab-induced hypertension: pathogenesis and management.
Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
14. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer.
Morita S; Uehara K; Nakayama G; Shibata T; Oguri T; Inada-Inoue M; Shimokata T; Sugishita M; Mitsuma A; Ando Y
Cancer Chemother Pharmacol; 2013 Feb; 71(2):405-11. PubMed ID: 23161411
[TBL] [Abstract][Full Text] [Related]
15. Treatment of bevacizumab-induced hypertension by amlodipine.
Mir O; Coriat R; Ropert S; Cabanes L; Blanchet B; Camps S; Billemont B; Knebelmann B; Goldwasser F
Invest New Drugs; 2012 Apr; 30(2):702-7. PubMed ID: 20878444
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer.
Nakaya A; Kurata T; Yokoi T; Iwamoto S; Torii Y; Katashiba Y; Ogata M; Hamada M; Kon M; Nomura S
Cancer Med; 2016 Jul; 5(7):1381-7. PubMed ID: 27109438
[TBL] [Abstract][Full Text] [Related]
17. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
18. VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?
le Noble FAC; Mourad JJ; Levy BI; Struijker-Boudier HAJ
Hypertension; 2023 May; 80(5):901-911. PubMed ID: 36748474
[TBL] [Abstract][Full Text] [Related]
19. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
20. Management of hypertension in angiogenesis inhibitor-treated patients.
Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
